Dupixent approved in US for adults with poorly controlled COPD
WEB6 hours ago — by Margarida Maia, PhD September 30, 2024. The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation ...
Dupixent Approved as Add-On Maintenance Therapy in COPD
WEB5 hours ago — Both trials enrolled COPD patients with moderate to severe airflow limitation (post-bronchodilator FEV 1 /FVC ratio <0.7 and post-bronchodilator FEV 1 of 30% to 70% predicted) and a minimum blood ...
Press Release: Dupixent approved in the US as the first-ever ...
WEB3 days ago — 30% and 34% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks, the primary endpoint. 74mL and 68mL numerically greater improvements in post-bronchodilator FEV ...
A New COPD Treatment is FDA Approved | COPD Foundation
WEBJul 8, 2024 — On June 26, 2024, Verona Pharmaceuticals announced that its new medication, Ensifentrine (Ohtuvayre), was approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). See the press release here.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever ...
WEB3 days ago — News + Insights. News and Insights-> Markets-> Companies-> Cryptocurrency-> ... About the Dupixent COPD Phase 3 Trial ProgramBOREAS and NOTUS were replicate, randomized, Phase 3, double-blind ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB3 days ago — European regulators approved Dupixent for COPD in July, but Regeneron and Sanofi have had to wait longer in the U.S., where the FDA requested additional efficacy data from the two trials. Over that time, a potential new competitor has emerged in GSK’s Nucala, which the FDA rejected in 2018 but earlier this month succeeded in a Phase 3 trial.
New Advances in Managing COPD | TIME
WEBMar 18, 2024 — From innovative new lung valves to refinements in the deployment of inhaled therapies and vaccines, the landscape of COPD care and treatment is changing.
COPD News - ScienceDaily
WEB5 days ago — Latest research news on COPD, including chronic bronchitis, chronic obstructive airway disease, chronic obstructive lung disease and emphysema.
Dupixent found to prevent COPD ... - COPD News Today
WEBApr 3, 2023 — Dupixent (dupilumab) — a medication initially approved for exzema — was found to significantly reduce the number of disease exacerbations and to improve lung function in people with chronic obstructive pulmonary disease (COPD), meeting the primary and key secondary goals of the pivotal Phase 3 BOREAS trial. A …
Dupixent eases flares, aids lung function with COPD: NOTUS trial
WEBJun 17, 2024 — Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe …